<DOC>
	<DOCNO>NCT01139021</DOCNO>
	<brief_summary>One year antibody persistence fourth dose boost two catch-up dos administer start 12 month age evaluate response third dose boost two catch-up dose start 24 month age .</brief_summary>
	<brief_title>One Year Antibody Persistence After Fourth Dose Boost Two Catch-Up Doses Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months Age Response Third Dose Boost Two Catch-Up Doses Starting 24 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Healthy male female child , 23 27 month age ( naïve child ) Available visit schedule study ; For parent ( ) /legal guardian ( ) give write informed consent accord local regulation nature study explain ; Available visit schedule study ; In good health determine medical history , physical examination , clinical judgment investigator . Healthy child participate immunogenicity part V72P13E1 receive last vaccination 12 month ( 30/+60 day ) enrolment V72P13E2 ; Who receive vaccination rMenB+OMV NZ V72P13 V72P13E1 accord protocol ; Who provide least blood sample one month fourth dose rMenB+OMV NZ ( group B246_12M12/B246_12M13 ) second dose rMenB+OMV NZ ( group B13_15_27/B12_14_26 ) V72P13E1 accord protocol ; For parent ( ) /legal guardian ( ) give write informed consent nature study explain ; In good health determine medical history , physical examination , clinical judgment investigator . Subjects whose parent ( ) /legal guardian ( ) unwilling unable give write informed consent participate study ; History meningococcal B vaccine administration ; Previous ascertain suspected disease cause N. meningitidis ; For parent ( ) /legal guardian ( ) give write informed consent accord local regulation nature study explain ; History severe allergic reaction previous vaccination hypersensitivity vaccine component ; Antibiotics treatment within 6 day prior enrolment ; Household contact and/or intimate exposure individual laboratory confirm N. meningitidis ; Any serious chronic progressive disease Known suspect impairment/ alteration immune system , Receipt , intent immunize another vaccine , within 30 day prior vaccination investigational vaccine ( within 14 day license flu vaccine ) Significant acute chronic infection within previous 7 day axillary temperature ≥38C within previous day ; Family member household member research staff ; Any serious chronic progressive disease accord judgment investigator ( e.g. , neoplasm , diabetes mellitus Type I , cardiac disease , hepatic disease , neurological disease seizure , either associate fever part underlie neurological disorder syndrome , autoimmune disease , Human Immunodeficiency Virus ( HIV ) infection Acquired Immune Deficiency Syndrome ( AIDS ) , blood dyscrasia diathesis , sign cardiac renal failure severe malnutrition ) ; Known suspected impairment/alteration immune system , immunosuppressive therapy , use systemic corticosteroid chronic use inhale highpotency corticosteroid within 30 day prior enrolment ( use low moderate dos inhale steroid exclusion ) ; Receipt blood , blood product and/or plasma derivative parenteral immunoglobulin preparation within 90 day prior enrolment ; Participation another clinical trial within 90 day prior enrolment plan study ; Receipt , intent immunize vaccine ( ) within 30 day prior enrolment ( exception : fluvaccines administer within 14 day prior enrolment ) ; Any condition , opinion investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>23 Months</minimum_age>
	<maximum_age>27 Months</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Children</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>Prevention</keyword>
	<keyword>Vaccination</keyword>
</DOC>